A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers TOPAZ-1

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03875235

Study #:
STUDY00144447

Start Date:
Apr 23, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03875235

View Complete Trial Details & Eligibility at ClinicalTrials.gov